What is AviadoBio?
Founded in 2019 and headquartered in London, UK, AviadoBio is a pioneering gene therapy company dedicated to addressing debilitating neurological diseases. The company's strategic focus on this complex area of medicine highlights its commitment to developing innovative treatments for unmet medical needs. AviadoBio's approach leverages cutting-edge gene therapy techniques to potentially offer new therapeutic avenues for patients suffering from severe neurological conditions.
How much funding has AviadoBio raised?
AviadoBio has raised a total of $80M across 1 funding round:
Series A
$80M
Series A (2021): $80M with participation from New Enterprise Associates and Monograph Capital
Key Investors in AviadoBio
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm established in 1977, known for its focus on supporting entrepreneurs in building impactful businesses across various sectors.
Monograph Capital
Monograph Capital is an investment entity that participated in AviadoBio's funding round. Further details on their specific investment focus are not publicly disclosed.
What's next for AviadoBio?
The substantial enterprise-level funding AviadoBio has attracted signals a strong investor confidence in its scientific approach and market potential. This capital infusion is expected to accelerate the company's research and development pipeline, potentially enabling the advancement of its gene therapy candidates through critical clinical trial stages. AviadoBio is poised to make significant strides in the gene therapy landscape, aiming to translate its scientific discoveries into tangible patient benefits and establish itself as a leader in neurological disease treatment.
See full AviadoBio company page
